Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.06 Consensus Target Price from Analysts
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has issued a strong buy recommendation on […]
More Stories
Champions League final: PSG storms past Inter Milan to win first European title by record margin
By Henry Bushnell For a little over a decade, Paris Saint-Germain was a controversial project and a collection of names. It was...
US Personal Income Growth Accelerates in April, Surges 0.8 Percent
By Andrew Moran U.S. consumers earned more income, saved more money, and spent less in April, new U.S. government data...
House Megabill to Expand Health Savings Account Eligibility and Benefits
By Kevin Stocklin The One Big Beautiful Bill Act, passed by the House of Representatives on May 22 and currently...
Trump Envoy Rejects Hamas Response to Gaza Cease-Fire Proposal as ‘Totally Unacceptable’
By Tom Ozimek President Donald Trump’s special envoy to the Middle East has dismissed the Hamas response to a U.S.-backed...
Automotive Stocks To Watch Today – May 29th
NVIDIA, Tesla, and Salesforce are the three Automotive stocks to watch today, according to MarketBeat’s stock screener tool. Automotive stocks...
Automotive Stocks To Watch Today – May 29th
NVIDIA, Tesla, and Salesforce are the three Automotive stocks to watch today, according to MarketBeat’s stock screener tool. Automotive stocks...